Table 1.

Mean ages and venous thromboembolism incidence rates of patients with rheumatoid arthritis initiating treatment with tofacitinib or TNF blockers

Age and IR	Truven (tofacitinib)	Truven (TNF blocker)	Medicare (tofacitinib)	Medicare (TNF blocker)
n	1910	32,164	995	16,091
Mean age	54 ± 11.6	50 ± 12.7	71 ± 5.7	71 ± 5.9
IR per 100 PY	0.60 (0.26–1.19)	0.34 (0.27–0.41)	1.12 (0.45–2.31)	0.92 (0.76–1.11)

Data are presented as mean ± standard deviation or IR (95% confidence interval) unless otherwise indicated

CI confidence interval, IR incidence rate, PY person-year, TNF tumor necrosis factor